From Research Review NZ: Learn more about the primary prevention of cardiovascular and heart failure events with SGLT2 inhibitors, GLP-1 receptor agonists, and their combination in type 2 diabetes, with commentary by Ryan G Paul, Auckland NZ
Download: Study-Review-2022-Primary-prevention-of-CDX-and-Heart-Failure